Newsletter
| Promoter: | ExplosiveOTC | Paying Party: | Eden Media |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VDRM | $2500 | 13454 |
| Max Profit: 4.40 % | Gain at close: 1.65 % | |
| *We think that this promoter is a part of a group of promoters. | ||
 hi, i'm happy that you are here as a member of the Explosivecommunity, but if you ever feel you no longer want to receive my emails, please use the button to the right to un-list. Thank you much :) |
 |
|
Hi and good afternoon,
Tonight we’re looking at a little known biotech that has won some very prestigious awards, including the Bronze Award for Best New Pharmaceutical Product at the 25th Annual Edison Awards in New York City.
And it closed today at just 014 (that’ just north of a cent). Yet as it accumulates such honors who knows how much longer it will stay at these levels…
But before we get to that:
If you’ve been reading our reports since the start of this year then you’re already well aware that 2015 is off to an incredible start. So far we’ve seen two double-digit runs, four triple-digit runs and one amazing two day run that reached 1185 pct. All of this in just the first three weeks of the New Year.
We intend to keep this amazing run going, which brings us to tonight. I recognize, with few exceptions, day in and day out on the smaller markets the most active companies I follow are biotech / pharma.
Biotech / pharma companies are often among the most active movers on the small markets because the rewards can be incredible. For this reason people are always looking for the next Bio-Innovation. The trouble is that quality new entries into this market are few and far between… so traders end up obsessing over pre-clinical results from the same companies for years.
This is where tonight’s report gets interesting… so get ready to perk up. We’ve found a little known biotech / pharma company with a novel, patent-pending product that has performed very well in initial testing. I warn you, the following case studies contain images that are not for the faint of heart. But then again, we are talking about biology, injury, lacerations, burns… if you’re squeamish look beyond that and recognize the market size for potential applications:
http://viadermalicensing.com/img/ViaDermaCaseStudies.pdf
What we have here is not a normal report. There is nothing common about the medicinal advancements we are about to discuss. This company has enormous potential… and at the moment it is at only 016, that’s just over one cent!
Tonight’s new play is:
ViaDerma, Inc. (VDRM)
Website: http://viadermalicensing.com/
Quote: http://www.otcmarkets.com/stock/VDRM/quote
ViaDerma is a specialty pharma company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharma industry in a wide variety of therapeutic areas.
ViaDerma's lead product, TetraStem, is an FDA registered product that uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug.
And really, although TetraStem is the company’s leading product, the real innovation is the delivery method. Some medicines are taken in the form of a pill, some are given “sublingually” (absorbed under the toung), others are given as injections via needles directly into the blood stream. VDRM’s breakthrough is a “Transdermal Delivery”.
Basically, VDRM’s patent-pending dual carrier transdermal technology delivers medications into the body via a topical solution (a liquid or a cream or an ointment applied directly to the skin). These medicines may currently be delivered into the body by other means such as pills or injections, yet there are certain benefits to applying them as a topical solution.
According to National Institute of Health (NIH): “Transdermal drug delivery has made an important contribution to medical practice, but has yet to fully achieve its potential as an alternative to oral delivery and hypodermic injections”
In other words, the already enormous market has significant room for growth as it has several benefits:
VDRM’s patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.
TetraStem is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but more importantly has also shown to be effective in fighting more harmful forms of staph infections.
Now that is impressive. A 014 company that holds a drug of this magnitude that has already demonstrated its efficacy and is FDA-registered is practically unheard of.
This could be a unique opportunity so make sure you start on your research right away.
VDRM is developing products in many fields of use including:
Other potential markets for this technology include Sports Nutrition, Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases.
But the bottom line is, does it work?
Well, take a look at the following quote taken from a press release discussing the use of TetraStem as a treatment for acne:
"It has been tested in Florida, Oklahoma and California," said ViaDerma, Inc. CEO Dr. Christopher Otiko. "The subjects have been pleased with the results. They had tried other medication without success and were impressed with TetraStem's results."
VDRM’s technology has also received honors and awards from much of the Pharmaceutical community. This includes:
VDRM’s transdermal technology was used in a product that received the Bronze Award for “2012 Best New Pharmaceutical Product” at the 25th Annual Edison Awards in New York City.
The product was also named the winner of the “Drug Store News Best New Product” as voted by key pharmacy industry decision makers at the ECRM Marketgate 2012 meetings held in Charlotte, NC.
In case you missed it earlier in this profile, take a look at the results & case studies of TetraStem: http://viadermalicensing.com/img/ViaDermaCaseStudies.pdf
TetraStem is currently available for sale and ViaDerma management is actively working to expand distribution channels to meet growing demand.
The chart also has several Bullish indicators at the moment, including the short and medium-term MACD. The 7-Day Average Directional Indicator is Green as is the 50-Day Parabolic Time/Price. At the moment the Low Analysis is also Very Bullish.
Currently at just 016 (that’s just over one and a half cents) even a slight move could translate to big percentages.
With a groundbreaking, innovative, patent–pending new biotech product reaching into massive markets that even the NIH says has much more room to grow, VDRM could be on to something special…
… so get started on researching this exciting young biotech right away. The sky could be the limit.
Remember, we always encourage you to do further research. Never take our word for it, read our disclaimer to see why, and of course always consult a professional.
Just because a situation looks great things can still go wrong and often do. Be smart and protect yourself.
Enjoy your afternoon,
Exp
IMPORTANT NOTICE AND DISCLAIMER This is a paid email ad for the company or companies mentioned herein. This paid advertisement does not provide an analysis of any company's financial position, operations or prospects and as such this is not to be construed as a recommendation or a solicitation to buy or sell any security. Do not base any investment and/or financial decisions upon any of the materials found on our website or in our newsletter publication(s) such as this one. Market365, LLC, the publisher of this newsletter and the website(s) associated with this email publication and its affiliates and contractors are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice Our full disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list: Full Disclaimer Release of Liability: Through use of this newsletter or viewing or using our website(s), you agree to hold Market365, its operators, owners, employees and/or contractors harmless and to completely release them from any and all liability due to any and all losses (monetary or otherwise), damages (monetary or otherwise) that may occur and/or that you may incur. This is a paid email message: Market365 and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. Market365 is a media and advertising firm that is often compensated by the companies profiled in our newsletter(s) and/or on our website(s). Compensation is received in cash via bank wire. We never receive compensation in shares. All compensation is disclosed in our newsletter(s) and/or on our website(s). Compensation: We have been compensated two thousand five hundred dollars cash by a third party, Eden Media Group, for this marketing campaign of ViaDerma, Inc. All compensation is received via bank wire. We do not own any shares or hold any positions in ViaDerma, Inc. Conflict of Interest: We do not investigate the background of any third party. The third party may have shares and may liquidate them, which may negatively affect the stock price. The above compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Forward looking statements: The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Information: Market365 is committed to providing factual information on the companies that are profiled. However, we do not provide any assurances as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. Market365 has no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable. To the fullest extent of the law, Market365 will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the alert, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). Third Party Websites: This email may provide hyperlinks to third party websites or access to third party content. Market365, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Market365 control, endorse, or guarantee any content found in such sites. By accessing, viewing, or using the website or communications originating from this release, you agree that Market365, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Market365, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. This email is based entirely upon information gathered from public information. Although the information contained in this e-mail is believed to be reliable, Market365 makes no warranties as to the accuracy of the content of this e-mail, expressly disclaims and accepts no liability for how readers may choose to utilize the content of this e-mail. Market365 does not verify the validity of any press releases in this electronic communication. Readers are strongly urged to independently verify all statements made in this email and to perform their own due diligence on this or any other advertised company, including but not limited to consulting with a qualified investment professional, reviewing the publicly available financial statements of, and other information about these featured companies and verifying that an investment in that company is appropriate and suitable for you. Many companies have filed information with state securities regulators and many companies will supply prospective investors with additional information upon request. We encourage you to invest carefully and read investment information available at the websites of the SEC at www.sec.gov and FINRA at www.finra.org. |